DOCSLIB.ORG

Infectious Disease Antibodies and Antigens Since 1985 Supplying Researchers and Manufacturers with Infectious Disease Antibodies and Antigens Since 1985

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Infectious Disease Antibodies and Antigens Since 1985 Supplying Researchers and Manufacturers with Infectious Disease Antibodies and Antigens Since 1985 .....Viro Stat .....Viro Stat Supplying Researchers and Manufacturers with Infectious Disease Antibodies and Antigens Since 1985 Supplying Researchers and Manufacturers with Infectious Disease Antibodies and Antigens Since 1985 MONOTOPETM ............................. 4 Mouse Monoclonal Antibodies RECOMBINANT ANTIGENS ..........14 COMPANION REAGENTS .............14 MabyRabTM ..............................15 Rabbit Monoclonal Antibodies OMNITOPETM .............................16 Polyclonal Antibodies Ordering Information ...............18 Distributors .............................19 .....Viro Stat Founded in 1985 by Dr. Douglas McAllister, ViroStat manufactures and supplies infectious disease antibody tools to researchers and manufacturers in the areas of virology, bacteriology and parasitology. Applications for the antibodies include detection of respiratory agents, STD agents, gastrointestinal agents/toxins and food borne pathogens. The company offers more than 500 infectious disease reagents including their MONOTOPE™ monoclonal antibodies, OMNITOPE™ polyclonal antibodies, MabyRabTM rabbit monoclononal antibodies, and numerous recombinant antigens. Many of these antibodies are used by manufacturers of rapid, point of care tests currently made and sold in the United States. Specialties include high affinity antibodies to Flu A, Flu B, RSV & H. pylori, as well as antibodies to food-borne pathogens and toxins. Because ViroStat is the primary manufacturer of these antibodies, we have the knowledge and experience to offer excellent customer service and technical support to your laboratory staff on any scale from 100 ug to 10 grams. we are the primary manufacturer of 83% of our products MonotopeTM (Mouse) Monoclonal Antibodies* Agent Specificity Purified (100ug) FITC CONJ (100ug) Adenovirus 1410 Adenovirus hexon 1411 Adenovirus hexon 1421 Adenovirus hexon 1431 1433 Adenovirus hexon 1461 1463 Adenovirus hexon 1481 Adenovirus hexon 1491 Alphavirus group 3582 Aspergillus 5141 Astrovirus group 4981 Astrovirus 4982 Astrovirus 4983 Astrovirus 4984 Bacillus anthracis protective ag. 7825 Bacillus anthracis spore ag. 7826 Bacillus anthracis protective ag. 7821 Bacillus anthracis spore ag. 7827 BK virus VP1 4942 BK virus VP1 4943 Bordetella pertussis LPS 5111 Borrelia burgdorferi Osp A 0551 Borrelia burgdorferi Osp B 0561 Bovine Papillomavirus 5091 Bovine Papillomavirus 5095 Brucella abortus LPS 3531 Brucella abortus LPS 3535 Campylobacter jejuni 100 kDa 7711 Campylobacter jejuni 100 kDa 7721 Campylobacter jejuni 100 kDa 7731 Campylobacter jejuni 100 kDa 7741 Candida albicans 6401 Candida albicans pan 6402 Canine Distemper virus 7514 Canine Distemper virus 7515 ..... ViroStat Canine Heartworm 3217 Canine Heartworm 3231 Canine Heartworm 3232 Canine Heartworm 3233 Canine Parvovirus 7351 *For research and manufacturing Canine Parvovirus 7341 use only—not for use in Chikungunya virus 3583 diagnostic procedures. Chikungunya virus 3584 Chikungunya virus 3585 Chlamydia pneumoniae 1692 4 TM Monotope (Mouse) Monoclonal Antibodies* Agent Specificity Purified (100ug) FITC CONJ (100ug) Chlamydia pneumoniae 1697 $250 Chlamydia pneumoniae 1693 $250 Chlamydia pneumoniae 1694 $250 Chlamydia pneumoniae 1696 $250 Chlamydia - LPS LPS 1681 $250 1683 Chlamydia - LPS LPS 1685 $250 Chlamydia - LPS LPS 1645 $250 Chlamydia Trachomatis LPS 1644 $250 1649 Chlamydia Trachomatis LPS 1646 $250 Chlamydia Trachomatis LPS 1647 $250 Chlamydia Trachomatis LPS 1685 $250 Chlamydia Trachomatis MOMP 1655 $250 Chlamydia Trachomatis MOMP 1656 $250 Cholera toxin B subunit 7955 $250 Cholera toxin B subunit 7953 $250 Cholera toxin B subunit 7954 $250 Cl. botulinum D toxoid 5131 $250 Cl. difficile toxin B 5152 $250 Cl. difficile toxin B 5153 $250 Infectious Disease Cl. difficile toxin B 5156 $250 Antibodies and Cl. difficile toxin A 5157 $250 Antigens Cl. difficile toxin A 5150 $250 Cl. difficile toxin A 5154 $250 Cl. difficile toxin B 5158 $250 Cl. difficile toxin B 5159 $250 Cl. difficile toxin A 5155 $250 Clostridia GDH 5188 $250 Clostridia GDH 5186 $250 Clostridia GDH 5187 $250 Cryptosporidium parvum Oocysts 7631 $250 7633 Cryptosporidium parvum Oocysts 7601 $250 Cytomegalovirus gH 0861 $250 Cytomegalovirus late ag. 0881 $250 Cytomegalovirus late ag. 0898 $250 Cytomegalovirus late 65 kDa 0896 $250 Cytomegalovirus late 45 kDa 0897 $250 Cytomegalovirus gB 0826 $250 Cytomegalovirus immed. early 0841 $250 Cytomegalovirus 65 kDa matrix 0891 $250 Cytomegalovirus gB 0811 $250 *For research and manufacturing Cytomegalovirus immed. early 0851 $250 use only—not for use in Cytomegalovirus pp65 0885 $250 0887 diagnostic procedures. Dengue virus NS1 5160 $250 Dengue virus NS1 5162 $250 Continued on Page 6 5 MonotopeTM (Mouse) Monoclonal Antibodies* Agent Specificity Purified (100ug) FITC CONJ (100ug) Dengue virus NS1 5163 $250 Dengue virus NS1 5164 $250 Dengue virus NS1 5165 $250 Dengue virus NS1 5166 $250 Dengue virus NS1 5167 $250 Dengue virus NS1 5168 $250 Dengue virus NS1 5169 $250 Dengue virus NS1 5170 $250 Dengue virus env-III 5182 $250 Dengue virus env-III 5184 $250 Diphtheria toxin 7801 $250 Diphtheria toxin A subunit 7811 $250 Ebola virus NP 2601 $265 Ebola virus NP 2602 $265 Ebola virus NP 2603 $265 Ebola virus NP 2604 $265 Ebola virus VP40 2614 $265 Ebola virus VP40 2615 $265 Ebola virus VP40 2616 $265 Ebola virus VP40 2611 $265 Ebola virus VP40 2612 $265 Ebola virus VP40 2613 $265 E. coli O157 1061 $265 1063 E. coli common 1011 $250 E. coli O157 1025 $265 E. coli O157 1024 $265 E. coli K99 6911 $280 E. coli O157 1023 $265 E. coli O157 1022 $265 E. coli O157 1026 $265 Enolase fungal 6492 $250 Enolase fungal 6493 $250 Enolase fungal 6491 $250 Entamoeba histolytica 3552 $250 ..... ViroStat Entamoeba histolytica 3553 $250 Entamoeba histolytica 3554 $250 Entamoeba histolytica 3556 $250 Enterobacteriaciae ECA 1055 $250 Enterovirus Pan 3654 $250 *For research and manufacturing Enterovirus 70 3651 $250 use only—not for use in Enterovirus 71 VP1 3656 $250 diagnostic procedures. Enterovirus 71 VP1 3657 $250 Epstein-Barr virus Bcl-2 0235 $250 Epstein-Barr virus Bam H1 Z 0256 $250 6 TM Monotope (Mouse) Monoclonal Antibodies* Agent Specificity Purified (100ug) FITC CONJ (100ug) Epstein-Barr virus gp 250/350 0221 $250 0223 Epstein-Barr virus VCA 0231 $250 Epstein-Barr virus EA-D 0261 $250 Feline Leukemia virus FeLv gp70 7217 $250 Feline Leukemia virus FeLv p27 7218 $250 Feline Leukemia virus FeLv p27 7228 $250 Feline Leukemia virus FeLv p27 7226 $250 Flavivirus group 3571 $280 Francisella tularensis LPS 3511 $250 Francisella tularensis LPS 3515 $250 Giardia lamblia 65 kDa 6281 $250 Giardia lamblia 65 kDa 6231 $250 Giardia lamblia 65 kDa 6241 $250 Giardia lamblia 65 kDa 6261 $250 Giardia lamblia cysts 6271 $250 6273 Gram + bacteria LTA 3801 $250 Gram + bacteria LTA 3802 $250 Gram + bacteria LTA 3803 $250 Gram + bacteria LTA 3811 $250 Infectious Disease Hantavirus nucleocapsid 4956 $250 Antibodies and Hantavirus nucleocapsid 4957 $250 Antigens Hantavirus nucleocapsid 4958 $250 Helicobacter pylori 19 kDa 6621 $250 Helicobacter pylori 19 kDa 6631 $250 Helicobacter pylori 54 kDa 6641 $250 Helicobacter pylori 54 kDa 6651 $250 Helicobacter pylori 58 kDa 6661 $250 Helicobacter pylori 19 & 58 kDa 6671 $250 Hepatitis A virus 1887 $250 Hepatitis A virus 1889 $250 Hepatitis A virus VP3 1881 $250 Hepatitis A virus 1885 $250 Hepatitis A virus 1880 $250 Hepatitis B virus core antgen 1822 $250 Hepatitis B virus core antigen 1823 $250 Hepatitis B virus core antigen 1824 $250 Hepatitis B virus sAg. capture 1834 $250 Hepatitis B virus sAg. capture 1835 $250 Hepatitis B virus sAg. capture 1836 $250 Hepatitis B virus sAg. probe 1837 $250 *For research and manufacturing Hepatitis B virus sAg. probe 1838 $250 use only—not for use in Hepatitis B virus e antigen 1892 $250 diagnostic procedures. Hepatitis B virus e antigen 1893 $250 Hepatitis B virus e antigen 1894 $250 Continued on Page 8 7 MonotopeTM (Mouse) Monoclonal Antibodies* Agent Specificity Purified (100ug) FITC CONJ (100ug) Hepatitis B virus X protein 1882 $250 Hepatitis B virus X protein 1883 $250 Hepatitis B virus X protein 1884 $250 Hepatitis C virus NS5a 1877 $280 Hepatitis C virus core 1851 $280 Hepatitis C virus core 1862 $280 Hepatitis C virus core 1863 $280 Hepatitis C virus core 1864 $280 Hepatitis C virus core 1868 $280 Hepatitis C virus NS3 1847 $280 Hepatitis C virus NS3 1857 $280 Hepatitis C virus NS3 1859 $280 Hepatitis C virus NS3 1878 $280 Hepatitis C virus NS4a 1866 $280 Hepatitis C virus NS4a+b 1865 $280 Hepatitis C virus NS4b 1867 $280 Hepatitis C virus NS5a 1827 $280 Hepatitis C virus NS5b 1825 $280 Hepatitis C virus NS5b 1826 $280 Hepatitis C virus NS3 1828 $280 Hepatitis C virus NS3 1848 $280 Hepatitis C virus E1 1879 $280 Hepatitis C virus E2 1876 $280 Hepatitis C virus NS4b 1858 $280 Herpes simplex virus, 1&2 Thymidine kinase 0117 $250 Herpes simplex virus, 1&2 nuclear 0119 $250 Herpes simplex virus, 1&2 gD 0197 $250 Herpes simplex virus, 1&2 gD 0195 $250 0196 Herpes simplex virus, 1&2 gD 0198 $250 Herpes simplex virus, 1&2 gD 0199 $250 Herpes simplex virus, 1&2 gD 0194 $250 Herpes simplex virus, 1&2 gD 0190 $250 Herpes simplex virus, 1&2 gD 0192 $250 Herpes simplex virus, type 1 gE 0112 $250 ..... ViroStat Herpes simplex virus, type 2 gE 0111 $250 0113 Herpes simplex virus, type 2 gG 0116 $250 Herpes simplex virus, type 2 nuclear 0115 $250 Herpes simplex virus, type 2 gG 0125 $250 Herpes simplex virus, type 2 gG 0126 $250 *For research and manufacturing Herpes simplex virus, type 2 gG 0128 $250 use only—not for use in Herpes simplex virus, type
Load more

Recommended publications
  • Entry of Hepatitis B and C Viruses
    VIRAL HEPATITIS FORUM Getting Close Viralto Eradication Hepatitis Forum I. Basic Getting Research Close to Eradication I. Basic Research Entry of Hepatitis B and C Viruses Seungtaek Kim Severance Biomedical Science Institute, Institute of Gastroenterology, Department of Internal Medicine, Yonsei University Col- lege of Medicine, Seoul, Korea B형과 C형 간염 바이러스에 대한 최근의 분자, 세포생물학적인 발전은 간세포를 특이적으로 감염시키는 이들 바이러스에 대한 세포 수용체의 발굴과 더불어 그들의 작용 기전에 대해 더 자세한 정보들을 제공해주고 있다. 특히 C형 간염 바이러스의 경우, 간세포의 서로 다른 곳에 위치한 세포 수용체들이 바이러스의 세포 진입시에 바이러스 표면의 당단백질과 어떤 방식으로 서로 상호 작용하며 세포 내 신호 전달 과정을 거쳐 세포 안으로 들어오게 되는지 그 기전들이 서서히 드러나고 있다. 한편, B형 간염 바이러스의 경우, 오랫동안 밝혀내지 못했던 이 바이러스의 세포 수용체인 NTCP를 최근 발굴하게 됨으로써 세포 진입에 관한 연구에 획기적인 계기를 마련하게 되었으며 동시에 이를 저해할 수 있는 새로운 항바이러스제의 개발도 활기를 띠게 되었다. 임상적으로 매우 중요한 이 두 바이러스의 세포 진입에 관한 연구는 앞으로도 매우 활발하게 이루어질 것으로 기대된다. Keywords: B형 간염 바이러스, C형 간염 바이러스, 세포 진입, 신호 전달, NTCP There are five hepatitis viruses although their classes, genomes, and modes of transmission are different from each other. Of these, hepatitis B virus (HBV) and hepatitis C virus (HCV) are the most dangerous, life-threatening pathogens, which are also responsible for 80-90% of hepatocellular carcinoma. HBV belongs to hepadnaviridae (family) and it has double-strand DNA as its genome, however, its replication occurs via reverse transcription like retrovirus replication. In contrast, HCV belongs to flaviviridae (family) and has positive-sense, single-strand RNA as its genome.
    [Show full text]
  • Symposium on Viral Membrane Proteins
    Viral Membrane Proteins ‐ Shanghai 2011 交叉学科论坛 Symposium for Advanced Studies 第二十七期：病毒离子通道蛋白的结构与功能研讨会 Symposium on Viral Membrane Proteins 主办单位：中国科学院上海交叉学科研究中心 承办单位：上海巴斯德研究所 1 Viral Membrane Proteins ‐ Shanghai 2011 Symposium on Viral Membrane Proteins Shanghai Institute for Advanced Studies, CAS Institut Pasteur of Shanghai,CAS 30.11. – 2.12 2011 Shanghai, China 2 Viral Membrane Proteins ‐ Shanghai 2011 Schedule: Wednesday, 30th of November 2011 Morning Arrival Thursday, 1st of December 2011 8:00 Arrival 9:00 Welcome Bing Sun, Co-Director, Pasteur Institute Shanghai 9: 10 – 9:35 Bing Sun, Pasteur Institute Shanghai Ion channel study and drug target fuction research of coronavirus 3a like protein. 9:35 – 10:00 Tim Cross, Tallahassee, USA The proton conducting mechanism and structure of M2 proton channel in lipid bilayers. 10:00 – 10:25 Shy Arkin, Jerusalem, IL A backbone structure of SARS Coronavirus E protein based on Isotope edited FTIR, X-ray reflectivity and biochemical analysis. 10:20 – 10:45 Coffee Break 10:45 – 11:10 Rainer Fink, Heidelberg, DE Elektromechanical coupling in muscle: a viral target? 11:10 – 11:35 Yechiel Shai, Rehovot, IL The interplay between HIV1 fusion peptide, the transmembrane domain and the T-cell receptor in immunosuppression. 11:35 – 12:00 Christoph Cremer, Mainz and Heidelberg University, DE Super-resolution Fluorescence imaging of cellular and viral nanostructures. 12:00 – 13:30 Lunch Break 3 Viral Membrane Proteins ‐ Shanghai 2011 13:30 – 13:55 Jung-Hsin Lin, National Taiwan University Robust Scoring Functions for Protein-Ligand Interactions with Quantum Chemical Charge Models. 13:55 – 14:20 Martin Ulmschneider, Irvine, USA Towards in-silico assembly of viral channels: the trials and tribulations of Influenza M2 tetramerization.
    [Show full text]
  • Opportunistic Intruders: How Viruses Orchestrate ER Functions to Infect Cells
    REVIEWS Opportunistic intruders: how viruses orchestrate ER functions to infect cells Madhu Sudhan Ravindran*, Parikshit Bagchi*, Corey Nathaniel Cunningham and Billy Tsai Abstract | Viruses subvert the functions of their host cells to replicate and form new viral progeny. The endoplasmic reticulum (ER) has been identified as a central organelle that governs the intracellular interplay between viruses and hosts. In this Review, we analyse how viruses from vastly different families converge on this unique intracellular organelle during infection, co‑opting some of the endogenous functions of the ER to promote distinct steps of the viral life cycle from entry and replication to assembly and egress. The ER can act as the common denominator during infection for diverse virus families, thereby providing a shared principle that underlies the apparent complexity of relationships between viruses and host cells. As a plethora of information illuminating the molecular and cellular basis of virus–ER interactions has become available, these insights may lead to the development of crucial therapeutic agents. Morphogenesis Viruses have evolved sophisticated strategies to establish The ER is a membranous system consisting of the The process by which a virus infection. Some viruses bind to cellular receptors and outer nuclear envelope that is contiguous with an intri‑ particle changes its shape and initiate entry, whereas others hijack cellular factors that cate network of tubules and sheets1, which are shaped by structure. disassemble the virus particle to facilitate entry. After resident factors in the ER2–4. The morphology of the ER SEC61 translocation delivering the viral genetic material into the host cell and is highly dynamic and experiences constant structural channel the translation of the viral genes, the resulting proteins rearrangements, enabling the ER to carry out a myriad An endoplasmic reticulum either become part of a new virus particle (or particles) of functions5.
    [Show full text]
  • Hepatitis C Virus P7—A Viroporin Crucial for Virus Assembly and an Emerging Target for Antiviral Therapy
    Viruses 2010, 2, 2078-2095; doi:10.3390/v2092078 OPEN ACCESS viruses ISSN 1999-4915 www.mdpi.com/journal/viruses Review Hepatitis C Virus P7—A Viroporin Crucial for Virus Assembly and an Emerging Target for Antiviral Therapy Eike Steinmann and Thomas Pietschmann * TWINCORE †, Division of Experimental Virology, Centre for Experimental and Clinical Infection Research, Feodor-Lynen-Str. 7, 30625 Hannover, Germany; E-Mail: [email protected] † TWINCORE is a joint venture between the Medical School Hannover (MHH) and the Helmholtz Centre for Infection Research (HZI). * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +49-511-220027-130; Fax: +49-511-220027-139. Received: 22 July 2010; in revised form: 2 September 2010 / Accepted: 6 September 2010 / Published: 27 September 2010 Abstract: The hepatitis C virus (HCV), a hepatotropic plus-strand RNA virus of the family Flaviviridae, encodes a set of 10 viral proteins. These viral factors act in concert with host proteins to mediate virus entry, and to coordinate RNA replication and virus production. Recent evidence has highlighted the complexity of HCV assembly, which not only involves viral structural proteins but also relies on host factors important for lipoprotein synthesis, and a number of viral assembly co-factors. The latter include the integral membrane protein p7, which oligomerizes and forms cation-selective pores. Based on these properties, p7 was included into the family of viroporins comprising viral proteins from multiple virus families which share the ability to manipulate membrane permeability for ions and to facilitate virus production. Although the precise mechanism as to how p7 and its ion channel function contributes to virus production is still elusive, recent structural and functional studies have revealed a number of intriguing new facets that should guide future efforts to dissect the role and function of p7 in the viral replication cycle.
    [Show full text]
  • Viral Infection Modulates Mitochondrial Function
    International Journal of Molecular Sciences Review Viral Infection Modulates Mitochondrial Function Xiaowen Li 1,2,3, Keke Wu 1,2,3, Sen Zeng 1,2,3, Feifan Zhao 1,2,3, Jindai Fan 1,2,3, Zhaoyao Li 1,2,3, Lin Yi 1,2,3, Hongxing Ding 1,2,3, Mingqiu Zhao 1,2,3, Shuangqi Fan 1,2,3,* and Jinding Chen 1,2,3,* 1 College of Veterinary Medicine, South China Agricultural University, No. 483 Wushan Road, Tianhe District, Guangzhou 510642, China; [email protected] (X.L.); [email protected] (K.W.); [email protected] (S.Z.); [email protected] (F.Z.); [email protected] (J.F.); [email protected] (Z.L.); [email protected] (L.Y.); [email protected] (H.D.); [email protected] (M.Z.) 2 Guangdong Laboratory for Lingnan Modern Agriculture, College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China 3 Key Laboratory of Zoonosis Prevention and Control of Guangdong Province, Guangzhou 510642, China * Correspondence: [email protected] (S.F.); [email protected] (J.C.); Tel.: +86-20-8528-8017 (S.F.); +86-20-8528-8017 (J.C.) Abstract: Mitochondria are important organelles involved in metabolism and programmed cell death in eukaryotic cells. In addition, mitochondria are also closely related to the innate immunity of host cells against viruses. The abnormality of mitochondrial morphology and function might lead to a variety of diseases. A large number of studies have found that a variety of viral infec- tions could change mitochondrial dynamics, mediate mitochondria-induced cell death, and alter the mitochondrial metabolic status and cellular innate immune response to maintain intracellular survival.
    [Show full text]
  • APICAL M2 PROTEIN IS REQUIRED for EFFICIENT INFLUENZA a VIRUS REPLICATION by Nicholas Wohlgemuth a Dissertation Submitted To
    APICAL M2 PROTEIN IS REQUIRED FOR EFFICIENT INFLUENZA A VIRUS REPLICATION by Nicholas Wohlgemuth A dissertation submitted to Johns Hopkins University in conformity with the requirements for the degree of Doctor of Philosophy Baltimore, Maryland October, 2017 © Nicholas Wohlgemuth 2017 All rights reserved ABSTRACT Influenza virus infections are a major public health burden around the world. This dissertation examines the influenza A virus M2 protein and how it can contribute to a better understanding of influenza virus biology and improve vaccination strategies. M2 is a member of the viroporin class of virus proteins characterized by their predicted ion channel activity. While traditionally studied only for their ion channel activities, viroporins frequently contain long cytoplasmic tails that play important roles in virus replication and disruption of cellular function. The currently licensed live, attenuated influenza vaccine (LAIV) contains a mutation in the M segment coding sequence of the backbone virus which confers a missense mutation (alanine to serine) in the M2 gene at amino acid position 86. Previously discounted for not showing a phenotype in immortalized cell lines, this mutation contributes to both the attenuation and temperature sensitivity phenotypes of LAIV in primary human nasal epithelial cells. Furthermore, viruses encoding serine at M2 position 86 induced greater IFN-λ responses at early times post infection. Reversing mutations such as this, and otherwise altering LAIV’s ability to replicate in vivo, could result in an improved LAIV development strategy. Influenza viruses infect at and egress from the apical plasma membrane of airway epithelial cells. Accordingly, the virus transmembrane proteins, HA, NA, and M2, are all targeted to the apical plasma membrane ii and contribute to egress.
    [Show full text]
  • The SARS-Coronavirus Infection Cycle: a Survey of Viral Membrane Proteins, Their Functional Interactions and Pathogenesis
    International Journal of Molecular Sciences Review The SARS-Coronavirus Infection Cycle: A Survey of Viral Membrane Proteins, Their Functional Interactions and Pathogenesis Nicholas A. Wong * and Milton H. Saier, Jr. * Department of Molecular Biology, Division of Biological Sciences, University of California at San Diego, La Jolla, CA 92093-0116, USA * Correspondence: [email protected] (N.A.W.); [email protected] (M.H.S.J.); Tel.: +1-650-763-6784 (N.A.W.); +1-858-534-4084 (M.H.S.J.) Abstract: Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is a novel epidemic strain of Betacoronavirus that is responsible for the current viral pandemic, coronavirus disease 2019 (COVID- 19), a global health crisis. Other epidemic Betacoronaviruses include the 2003 SARS-CoV-1 and the 2009 Middle East Respiratory Syndrome Coronavirus (MERS-CoV), the genomes of which, particularly that of SARS-CoV-1, are similar to that of the 2019 SARS-CoV-2. In this extensive review, we document the most recent information on Coronavirus proteins, with emphasis on the membrane proteins in the Coronaviridae family. We include information on their structures, functions, and participation in pathogenesis. While the shared proteins among the different coronaviruses may vary in structure and function, they all seem to be multifunctional, a common theme interconnecting these viruses. Many transmembrane proteins encoded within the SARS-CoV-2 genome play important roles in the infection cycle while others have functions yet to be understood. We compare the various structural and nonstructural proteins within the Coronaviridae family to elucidate potential overlaps Citation: Wong, N.A.; Saier, M.H., Jr.
    [Show full text]
  • Incorporation of Hepatitis C Virus E1 and E2 Glycoproteins: the Keystones on a Peculiar Virion
    Viruses 2014, 6, 1149-1187; doi:10.3390/v6031149 OPEN ACCESS viruses ISSN 1999-4915 www.mdpi.com/journal/viruses Review Incorporation of Hepatitis C Virus E1 and E2 Glycoproteins: The Keystones on a Peculiar Virion Gabrielle Vieyres 1,*, Jean Dubuisson 2,3,4,5 and Thomas Pietschmann 1 1 Institute of Experimental Virology, Twincore, Center for Experimental and Clinical Infection Research, a Joint Venture between the Medical School Hannover and the Helmholtz Center for Infection Research, 30625 Hannover, Germany; E-Mail: [email protected] 2 Institut Pasteur de Lille, Center for Infection & Immunity of Lille (CIIL), F-59019 Lille, France; E-Mail: [email protected] 3 CNRS UMR8204, F-59021 Lille, France 4 Inserm U1019, F-59019 Lille, France 5 Université Lille Nord de France, F-59000 Lille, France * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +49-511-22-00-27-134; Fax: +49-511-22-00-27-139. Received: 18 December 2013; in revised form: 21 February 2014 / Accepted: 27 February 2014 / Published: 11 March 2014 Abstract: Hepatitis C virus (HCV) encodes two envelope glycoproteins, E1 and E2. Their structure and mode of fusion remain unknown, and so does the virion architecture. The organization of the HCV envelope shell in particular is subject to discussion as it incorporates or associates with host-derived lipoproteins, to an extent that the biophysical properties of the virion resemble more very-low-density lipoproteins than of any virus known so far. The recent development of novel cell culture systems for HCV has provided new insights on the assembly of this atypical viral particle.
    [Show full text]
  • Multiple Origins of Viral Capsid Proteins from Cellular Ancestors
    Multiple origins of viral capsid proteins from PNAS PLUS cellular ancestors Mart Krupovica,1 and Eugene V. Kooninb,1 aInstitut Pasteur, Department of Microbiology, Unité Biologie Moléculaire du Gène chez les Extrêmophiles, 75015 Paris, France; and bNational Center for Biotechnology Information, National Library of Medicine, Bethesda, MD 20894 Contributed by Eugene V. Koonin, February 3, 2017 (sent for review December 21, 2016; reviewed by C. Martin Lawrence and Kenneth Stedman) Viruses are the most abundant biological entities on earth and show genome replication. Understanding the origin of any virus group is remarkable diversity of genome sequences, replication and expres- possible only if the provenances of both components are elucidated sion strategies, and virion structures. Evolutionary genomics of (11). Given that viral replication proteins often have no closely viruses revealed many unexpected connections but the general related homologs in known cellular organisms (6, 12), it has been scenario(s) for the evolution of the virosphere remains a matter of suggested that many of these proteins evolved in the precellular intense debate among proponents of the cellular regression, escaped world (4, 6) or in primordial, now extinct, cellular lineages (5, 10, genes, and primordial virus world hypotheses. A comprehensive 13). The ability to transfer the genetic information encased within sequence and structure analysis of major virion proteins indicates capsids—the protective proteinaceous shells that comprise the that they evolved on about 20 independent occasions, and in some of cores of virus particles (virions)—is unique to bona fide viruses and these cases likely ancestors are identifiable among the proteins of distinguishes them from other types of selfish genetic elements cellular organisms.
    [Show full text]
  • Design and Synthesis of Hepatitis C Virus NS3 Protease Inhibitors
    Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 282 Design and Synthesis of Hepatitis C Virus NS3 Protease Inhibitors BY ANJA JOHANSSON ACTA UNIVERSITATIS UPSALIENSIS UPPSALA 2003 Dissertation for the Degree of Doctor of Philosophy (Faculty of Pharmacy) in Medicinal Chemistry presented at Uppsala University in 2003. ABSTRACT Johansson, A. 2003. Design and Synthesis of Hepatitis C Virus NS3 Protease Inhibitors. Acta Universitatis Upsaliensis. Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 282. 79 pp. Uppsala. ISBN 91-554- 5538-7. Hepatitis C Virus (HCV) is the leading cause of chronic liver disease worldwide as well as the primary indication for liver transplantation. More than 3% of the world’s population is chronically infected with HCV and there is an urgent need for effective therapy. NS3 protease, a viral enzyme required for propagation of HCV in humans, is a promising target for drug development in this area. This thesis addresses the design, synthesis and biochemical evaluation of new HCV NS3 protease inhibitors. The main objective of the thesis was the synthesis of peptide-based protease inhibitors of the bifunctional full-length NS3 enzyme (protease-helicase/NTPase). Three types of inhibitors were synthesized: i) classical serine protease inhibitors with electrophilic C-terminals, ii) product-based inhibitors with a C-terminal carboxylate group, and iii) product-based inhibitors with C-terminal carboxylic acid bioisosteres. The developmental work included the establishment of an improved procedure for solid-phase peptide synthesis (SPPS) in the N-to-C direction, in contrast to the C-to-N direction of classical SPPS methods.
    [Show full text]
  • Innate Immune Antagonism by Diverse Coronavirus Phosphodiesterases Stephen Goldstein University of Pennsylvania, [email protected]
    University of Pennsylvania ScholarlyCommons Publicly Accessible Penn Dissertations 2019 Innate Immune Antagonism By Diverse Coronavirus Phosphodiesterases Stephen Goldstein University of Pennsylvania, [email protected] Follow this and additional works at: https://repository.upenn.edu/edissertations Part of the Allergy and Immunology Commons, Immunology and Infectious Disease Commons, Medical Immunology Commons, and the Virology Commons Recommended Citation Goldstein, Stephen, "Innate Immune Antagonism By Diverse Coronavirus Phosphodiesterases" (2019). Publicly Accessible Penn Dissertations. 3363. https://repository.upenn.edu/edissertations/3363 This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/3363 For more information, please contact [email protected]. Innate Immune Antagonism By Diverse Coronavirus Phosphodiesterases Abstract Coronaviruses comprise a large family of viruses within the order Nidovirales containing single-stranded positive-sense RNA genomes of 27-32 kilobases. Divided into four genera (alpha, beta, gamma, delta) and multiple newly defined subgenera, coronaviruses include a number of important human and livestock pathogens responsible for a range of diseases. Historically, human coronaviruses OC43 and 229E have been associated with up to 30% of common colds, while the 2002 emergence of severe acute respiratory syndrome- associated coronavirus (SARS-CoV) first raised the specter of these viruses as possible pandemic agents. Although the SARS-CoV pandemic was quickly contained and the virus has not returned, the 2012 discovery of Middle East respiratory syndrome-associated coronavirus (MERS-CoV) once again elevated coronaviruses to a list of global public health threats. The eg netic diversity of these viruses has resulted in their utilization of both conserved and unique mechanisms of interaction with infected host cells. Like all viruses, coronaviruses encode multiple mechanisms for evading, suppressing, or otherwise circumventing host antiviral responses.
    [Show full text]
  • Characterization of Nonprimate Hepacivirus and Construction of a Functional Molecular Clone
    Characterization of nonprimate hepacivirus and construction of a functional molecular clone Troels K. H. Scheela,b,c, Amit Kapoord, Eiko Nishiuchia, Kenny V. Brocke, Yingpu Yua, Linda Andrusa, Meigang Gua, Randall W. Renshawf, Edward J. Dubovif, Sean P. McDonoughg, Gerlinde R. Van de Walleh, W. Ian Lipkind, Thomas J. Diversi, Bud C. Tennanti, and Charles M. Ricea,1 aLaboratory of Virology and Infectious Disease, Center for the Study of Hepatitis C, The Rockefeller University, New York, NY 10065; bCopenhagen Hepatitis C Program, Department of Infectious Disease and Clinical Research Centre, Copenhagen University Hospital, DK-2650 Hvidovre, Denmark; cDepartment of International Health, Immunology, and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2200 Copenhagen, Denmark; dCenter for Infection and Immunity, Columbia University, New York, NY 10032; eDepartment of Biomedical Sciences, Edward Via College of Osteopathic Medicine, Auburn, AL 36866; and fVirology Laboratory, Animal Health Diagnostic Center, gDepartment of Biomedical Sciences, hBaker Institute for Animal Health, and iDepartment of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853 Contributed by Charles M. Rice, January 8, 2015 (sent for review November 17, 2014; reviewed by Harvey Alter and Volker Lohmann) Nonprimate hepacivirus (NPHV) is the closest known relative of associated virus, TDAV) (13, 14) pegiviruses were discovered. In- hepatitis C virus (HCV) and its study could enrich our understanding terestingly, strong epidemiological evidence links serum hepatitis of HCV evolution, immunity, and pathogenesis. High seropositivity of horses (Theiler’s disease) to infection with TDAV (13). is found in horses worldwide with ∼3% viremic. NPHV natural his- The NPHV genome resembles that of HCV, with a long ORF tory and molecular virology remain largely unexplored, however.
    [Show full text]